EUCTR2017-002136-16-IT进行中（未招募）1 期
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis - Diabetic Gastroparesis Study 1
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 2,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male and female participants aged 18 years or older at screening (Visit 1)
- •2. T1DM or T2DM of at least 5 years' duration, with controlled and stable blood glucose levels (ie, no episodes of diabetic
- •ketoacidosis, Hyperosmolar Hyperglycemic Nonketotic Diabetic Syndrome, or severe hypoglycemia within the 6 months preceding screening [Visit 1])
- •3. HbA1c .11.0% at screening (Visit 1) in participants being treated with oral and/or parenteral medications for T1DM or T2DM
- •with the goal of achieving controlled and stable glucose levels
- •4. DG defined as at least a 3-month history prior to screening (Visit 1) of symptoms on an ongoing basis that are suggestive of GP
- •(eg, nausea, abdominal pain, post-prandial fullness, bloating, vomiting, and early satiety)
- •5. Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period
- •A female participant is eligible to participate if she is not pregnant (has a negative urine pregnancy result prior to randomization),
- •not breastfeeding, and at least one of the following conditions applies:
- •a. Not a woman of childbearing potential (WOCBP)
- •b. A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 7 days after the last
- •dose of study treatment
- •6. Documentation of absence of an obstructing lesion on upper endoscopy or other equivalent diagnostic test, performed at some time before screening (Visit 1) but after the appearance of symptoms that led to the diagnosis of DG
- •7. At least 2 vomiting episodes during the 2 weeks prior to screening (Visit 1), as ascertained by participant history
- •8. Delayed GE confirmed by abnormal GEBT, defined as GE half-time (t1 / 2) a 79 minutes at the start of the placebo-controlled Run-in Period (Visit 2). In countries where the GEBT is not available, delayed GE may be confirmed by abnormal scintigraphy result (> 60% retention at 2 hours or > 10% at 4 hours)
- •9. BMI > 18.5 kg/m2
- •10. Able to provide written informed consent (IC) prior to any study procedures and willing and able to comply with study
- •Additional inclusion criteria for randomization after the 2-week, placebo Run-in Period:
- •11. Compliance with the entry of data into the hand-held electronic device on at least 10 of 14 days during the placebo Run-in
- •12. Compliance with administration of SC twice daily injections, as evidenced by entries made by the participant using the
- •electronic, hand-held device on at least 10 of 14 days during the placebo Run-in Period
- •13. At least one vomiting episode at any time during the placebo Run-in Period, as recorded in the DGSSD, using the electronic
- •hand-held device
- •14. The average of the daily DGSSS from the 2-week, placebo Run-in Period must be >= a 16
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1875
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 625
排除标准
- •1. Symptomatic Irritable Bowel Syndrome at Screening (Visit 1)
- •2. Small intestinal bacterial overgrowth (SIBO) at Screening (Visit 1)
- •3. History of anorexia nervosa, binge-eating, bulimia, or other eating disorder within 5 years of screening (Visit 1)
- •4. History of intestinal malabsorption (including celiac disease even if well-controlled on a gluten-free diet) or pancreatic exocrine
- •insufficiency; also, history of non-celiac gluten sensitivity
- •5. History of belching disorders, other nausea and vomiting disorders (eg, chronic nausea and vomiting syndrome, cyclic vomiting
- •syndrome, cannabinoid hyperemesis syndrome), or rumination syndrome
- •6. History of chronic obstructive pulmonary disease or other causes of pulmonary dysfunction that have resulted in CO2 retention
- •7. Gastric or duodenal ulcer within 3 months of Screening (Visit 1)
- •8. Evidence of hepatic disease defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 3 x ULN, and/or
- •direct bilirubin 2 x ULN
- •9. History of malignancy in the 3 years prior to Visit 1, except for adequately treated basal cell or squamous cell skin cancer, or in
- •situ cervical cancer
- •10. Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube for feeding or decompression
- •11. Use of metoclopramide, domperidone, prucalopride, macrolide antibiotics (eg, erythromycin, clarithromycin, azithromycin), or
- •other drugs considered to be GI pro-motility agents for at least 10 days prior to the start of the Run-in Period (Visit 2)
- •12. Positive results on the urine drug screen at Screening (Visit 1). The significance of a positive screen result for drugs prescribed
- •for the participant (e.g., barbiturates, benzodiazepines, amphetamines, but not cannabinoids) should be assessed by the
- •Investigator as to whether their stable-dose usage is clinically appropriate, and, therefore, should not be exclusionary; use of these
- •drugs on an as-needed basis is not allowed
- •13. Currently taking opioids, or expecting to use opioids during the course of the clinical study
- •14. Treatment with glucagon-like peptide-1(GLP-1) agonist for at least 6 weeks prior to the start of the Run-in Period (Visit 2)
- •15. History of pyloric injection of botulinum toxin within 6 months of screening
- •16. History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure
- •(a history of diagnostic endoscopy is not exclusionary)
- •17. Randomization in any previous study in which relamorelin was a treatment
- •18. Estimated glomerular filtration rate (eGFR) of < 30 mL/min
- •19. Current enrollment in an investigational drug or device tud articipation in such a study within 30 days of entry into this
- •20. Allergic to, or intolerant of egg, wheat, milk, or algae, a these are components of the GEBT study meal
- •21. Females who are pregnant, nursing, or planning a pregnancy during the study
- •22. The participant has a condition or is in a situation which, in the investigator's opinion, may put the participant at significant
- •risk, may confound the study results, or may interfere significantly with the participant's participation in the study
- •23. Participant is directly or indirectly involved in the conduct and administration of this study as an investigator, subinvestigator,
- •study coordinator, other study staff member, or employee of Allergan, Inc.; or the participant is a first-degree family member,
- •significant other, or relative residing with one of the above persons
研究者
相似试验
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersDiabetic GastroparesisEUCTR2017-002177-20-LVAllergan Ltd.2,500
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersDiabetic GastroparesisEUCTR2017-002177-20-ROAllergan Ltd.311
招募中
Unknown
A human study to evaluate the effect of CKDB001 on Cognitive-enhancing functioKCT0009298Chong Kun Dang Bio100
Unknown
2 期
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset SeizuresCTRI/2010/091/001332ovartis Health care Private Limited57
进行中（未招募）
1 期
A 12-week Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic GastroparesisDiabetic GastroparesisMedDRA version: 20.1Level: PTClassification code 10051153Term: Diabetic gastroparesisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2017-002177-20-GBAllergan Ltd.2,500